2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 464

Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis
Abstract Number: 465

Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Abstract Number: 466

Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Abstract Number: 467

Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid Arthritis
Abstract Number: 468

Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Abstract Number: 469

Effect of Patient Involvement in Treatment Decision Making on Disease Outcomes in Rheumatoid Arthritis in the USA
Abstract Number: 470

Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort
Abstract Number: 471

Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Abstract Number: 472

Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis
Abstract Number: 473

Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Abstract Number: 474

Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies
Abstract Number: 475

Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Abstract Number: 476

Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Abstract Number: 477

Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation
Abstract Number: 478

Ectopic Lymphoid Tissue in the Lung Is Uniquely Associated with the ACPA IgA Isotype Even in Absence of Classifiable RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].